BioCentury
ARTICLE | Clinical News

NIAID, HVTN launch African trial of HIV vaccine

February 20, 2015 2:18 AM UTC

NIH's National Institute of Allergy and Infectious Diseases (NIAID) and the HIV Vaccine Trials Network (HVTN) started the Phase I/II HVTN 100 trial in South Africa to evaluate combination vaccine HVTN 100 to prevent HIV infection. NIAID said it expects results in mid-2016.

The vaccine combines Alvac-HIV ( vCP205), a live recombinant canarypox vector vaccine expressing HIV gp120, HIV gag and HIV protease from Sanofi (Euronext:SAN; NYSE:SNY), with an HIV gp120 protein vaccine from Novartis AG (NYSE:NVS; SIX:NOVN). ...